Skip to main content
logo
Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.010
+0.025 (1.26%)
Oct 19, 2026, 12:03 PM EDT - Market open

Larimar Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
210326247200179191
Market Cap Growth
-42.19%32.06%23.61%11.79%-6.49%-41.88%
Enterprise Value
581554911060119
Last Close Price
1.993.813.874.554.1310.79

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
1.634.181.442.441.612.97
P/TBV Ratio
1.634.181.442.441.612.97

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.040.050.030.070.050.09
Net Debt / Equity Ratio
-1.19-1.70-1.04-0.99-1.02-0.99
Net Debt / EBITDA Ratio
0.850.771.971.963.121.28
Net Debt / FCF Ratio
0.971.172.502.424.091.51
Quick Ratio
4.582.127.589.1611.067.95
Current Ratio
4.702.198.029.4911.288.16
Return on Equity (ROE)
-139.63%-132.59%-63.59%-38.36%-40.33%-65.72%
Return on Assets (ROA)
-70.96%-62.31%-38.36%-23.48%-22.26%-34.40%
Return on Capital Employed (ROCE)
-136.50%-212.80%-51.70%-48.30%-31.60%-72.30%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-83.30%-50.80%-32.64%-18.50%-19.78%-26.50%
FCF Yield
-75.33%-34.74%-28.86%-16.83%-15.48%-22.21%
Buyback Yield / Dilution
-40.23%-19.09%-39.53%-70.42%-50.09%-44.44%
SEC Filings: 10-K · 10-Q